An ESD Model of Care for Older Adults Admitted to Hospital: a Protocol for a Descriptive Cohort Study

February 7, 2023 updated by: University of Limerick

An Early Supported Discharge Model of Care for Older Adults Admitted to Hospital: a Protocol for a Descriptive Cohort Study

The MidWest multidisciplinary Community Intervention Teams (MD-CIT) comprise of specialist, healthcare teams that provide a rapid and integrated response to a patient with an acute episode of illness who requires enhanced services/acute intervention for a defined short period of time in the MidWest of Ireland. This is provided in the patient's home, thereby facilitating early discharge from the acute hospital setting.

The investigators are performing an evaluation of the MDCIT service provided to older adults admitted to UL Hospitals Group. The investigators will assess patients in hospital, at 30 days and at a six months.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Anticipated)

150

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

65 years and older (Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Older adults admitted to general medical and surgical wards, trauma/orthopaedic wards and acute medical assessment units and subsequently discharged home with MDCIT support will be included.

Description

Inclusion Criteria:

  • Older adults ≥ 65 years who are discharged home (community dwelling) from ULHG with a referral to the MDCIT service between December 2022 and June 2023 will be deemed eligible for recruitment

Exclusion Criteria:

  • Those aged < 65 years discharged home from ULHG and referred to the MDCIT service
  • Those deemed to not have decision making capacity to provide informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Functional Ability
Time Frame: This will be measured at baseline.
Function will be measured using the Barthel Index (BI). The BI scores a patient from 0-20, with a higher score indicating greater independence.
This will be measured at baseline.
Functional Ability
Time Frame: This will be measured at 30 days.
Function will be measured using the Barthel Index (BI). The BI scores a patient from 0-20, with a higher score indicating greater independence.
This will be measured at 30 days.
Functional Ability
Time Frame: This will be measured at 180 days.
Function will be measured using the Barthel Index (BI). The BI scores a patient from 0-20, with a higher score indicating greater independence.
This will be measured at 180 days.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Frailty Score
Time Frame: This will be measured at baseline.
Frailty will be measured using the Clinical Frailty Scale (CFS). The CFS screens for frailty in older adults, with a minimum score of 1 considered least frail and a maximum score of 9 indicating severe frailty.
This will be measured at baseline.
Frailty Score
Time Frame: This will be measured at 30 days.
Frailty will be measured using the Clinical Frailty Scale (CFS). The CFS screens for frailty in older adults, with a minimum score of 1 considered least frail and a maximum score of 9 indicating severe frailty.
This will be measured at 30 days.
Frailty Score
Time Frame: This will be measured at 180 days.
Frailty will be measured using the Clinical Frailty Scale (CFS). The CFS screens for frailty in older adults, with a minimum score of 1 considered least frail and a maximum score of 9 indicating severe frailty.
This will be measured at 180 days.
Patient Quality of Life
Time Frame: This will be measured at baseline.
Quality of Life will be measured using the EQ-5D-5L. This questionnaire asks a patient to rate their overall perceived health from a scale of 0-100 (0 = very poor; 100 = excellent).
This will be measured at baseline.
Patient Quality of Life
Time Frame: This will be measured at 30 days.
Quality of Life will be measured using the EQ-5D-5L. This questionnaire asks a patient to rate their overall perceived health from a scale of 0-100 (0 = very poor; 100 = excellent).
This will be measured at 30 days.
Patient Quality of Life
Time Frame: This will be measured at 180 days.
Quality of Life will be measured using the EQ-5D-5L. This questionnaire asks a patient to rate their overall perceived health from a scale of 0-100 (0 = very poor; 100 = excellent).
This will be measured at 180 days.
Quality of Care
Time Frame: This will be measured at 30 days.
Quality of Care will be measured using the Patient Assessment of Integrated Elderly Care. Patients are asked 20 questions across a Likert scale from 'none at all' to 'always.'
This will be measured at 30 days.
Quality of Care
Time Frame: This will be measured at 1800 days.
Quality of Care will be measured using the Patient Assessment of Integrated Elderly Care. Patients are asked 20 questions across a Likert scale from 'none at all' to 'always.'
This will be measured at 1800 days.
Unscheduled ED Attendance(s)
Time Frame: This will be measured at 30 days.
ED hospital databases will be searched to identify ED attendances.
This will be measured at 30 days.
Unscheduled ED Attendance(s)
Time Frame: This will be measured at 180 days.
ED software will be searched to identify ED attendances.
This will be measured at 180 days.
Unscheduled Hospital Admission(s)
Time Frame: This will be measured at 30 days.
ED and hospital software will be searched to identify admissions.
This will be measured at 30 days.
Unscheduled Hospital Admission(s)
Time Frame: This will be measured at 180 days.
ED and hospital software will be searched to identify admissions.
This will be measured at 180 days.
Nursing Home Admission(s)
Time Frame: This will be measured at 30 days.
Hospital software will be searched to identify patients admitted to nursing homes.
This will be measured at 30 days.
Nursing Home Admission(s)
Time Frame: This will be measured at 180 days.
Hospital software will be searched to identify patients admitted to nursing homes.
This will be measured at 180 days.
Mortality
Time Frame: This will be measured at 30 days.
Hospital software will be searched to identify patients who pass away.
This will be measured at 30 days.
Mortality
Time Frame: This will be measured at 180 days.
Hospital software will be searched to identify patients who pass away.
This will be measured at 180 days.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Limerick

Investigators

  • Principal Investigator: Cathryn Ryan, MidWest Community Healthcare

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 5, 2022

Primary Completion (Anticipated)

June 30, 2023

Study Completion (Anticipated)

December 28, 2023

Study Registration Dates

First Submitted

January 20, 2023

First Submitted That Met QC Criteria

February 7, 2023

First Posted (Estimate)

February 16, 2023

Study Record Updates

Last Update Posted (Estimate)

February 16, 2023

Last Update Submitted That Met QC Criteria

February 7, 2023

Last Verified

January 1, 2023

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 112/2022

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Aging

Clinical Trials on MDCIT Intervention

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Brazil

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe